BARCLAY A PHILLIPS
CIK 1265801 · SVP & Chief Financial Officer · last filed 2026-07-07
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$15.3K
Companies
5
Total Filings
45
Lifetime Open-Market Net
-$7.70M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| IMUX | Director | — | $14.10 | — | $0 | 10 | 2026-07-07 |
| G1 Therapeutics, Inc. (GTHX) Delisted | SVP & Chief Financial Officer | 5,000 | $7.15 | $35.8K | -$199.6K | 3 | 2019-01-02 |
| NVAX | SVP, Chief Financial Officer | 1,933 | $7.89 | $15.3K | -$167.1K | 19 | 2017-08-01 |
| MICROMET, INC. (MITI) Delisted | SVP, CFO | 0 | — | — | -$213.6K | 9 | 2012-03-06 |
| Acorda Therapeutics, Inc. (ACOR) Delisted | Director | 2,778 | $0.66 | $1.8K | -$7.12M | 3 | 2008-06-16 |
Recent Filings · Page 2 of 5
45 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2019-01-02 | G1 Therapeutics, Inc. (GTHX) Delisted | Grant (A) | — | $0 | EDGAR |
| 2018-11-16 | G1 Therapeutics, Inc. (GTHX) Delisted | Mixed | — | -$102.3K | EDGAR |
| 2017-12-06 | G1 Therapeutics, Inc. (GTHX) Delisted | Grant (A) | — | $0 | EDGAR |
| 2017-08-01 | NVAX | Buy (P) | +2,057 | $1.8K | EDGAR |
| 2017-05-11 | NVAX | Buy (P) | +25,000 | $20.9K | EDGAR |
| 2017-02-02 | NVAX | Buy (P) | +1,633 | $1.8K | EDGAR |
| 2016-11-16 | NVAX | Grant (A) | — | $0 | EDGAR |
| 2016-08-02 | NVAX | Buy (P) | +422 | $1.8K | EDGAR |
| 2016-03-17 | NVAX | Grant (A) | — | $0 | EDGAR |
| 2016-02-01 | NVAX | Buy (P) | +405 | $1.8K | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.